

John Rizk

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4893248/john-rizk-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12
papers

244
citations

6
h-index

15
g-index

21
ext. papers

574
ext. citations

6.8
avg, IF

4.15
L-index

#	Paper	IF	Citations
12	Pharmaco-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020 , 80, 1267-1292	12.1	128
11	Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. <i>JAMA Cardiology</i> , 2021 ,	16.2	29
10	Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. <i>Drug Discovery Today</i> , 2021 , 26, 593-603	8.8	18
9	Cefiderocol: A Siderophore Cephalosporin. <i>Annals of Pharmacotherapy</i> , 2020 , 54, 1215-1231	2.9	14
8	Blood lactate concentration in COVID-19: a systematic literature review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 ,	5.9	5
7	Novel approaches to management of hyperkalaemia in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 27-37	3.5	5
6	Anticoagulation management strategies in heart transplantation. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 210-218	8.5	4
5	AuthorsdReply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19". <i>Drugs</i> , 2020 , 80, 1501-1503	12.1	4
4	The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action. <i>Vaccine</i> , 2021 , 39, 6017-6018	4.1	2
3	Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. <i>Clinical Respiratory Journal</i> , 2019 , 13, 663-673	1.7	1
2	Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.. <i>Drugs</i> , 2021 , 82, 43	12.1	1
1	Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 1	10.5	0